News Breaks |
|
|
| February 14, 2013 |
| 05:55 EDT |  | DVA, DVA, WLP, WLP, MCK, MCK, CI, CI, BMY, BMY, MDT, MDT, COV, COV, BAYRY, BAYRY, EPOC, EPOC, AET, AET, AGN, AGN, HUM, HUM, BDX, BDX | Wharton School of Business to host a conference
19th Annual Wharton Healthcare Business Conference is being held in Philadelphia on February 14-15. |
|
|
News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days Check below for free stories on DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX the last two weeks. |
|
|
| June 18, 2013 |
| 09:04 EDT | | AGN, MDT | Wells Faro to host a conference
2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link |
|
| 08:36 EDT |  | AGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| 08:30 EDT |  | BDX | JDRF extends collaboratoin with Becton Dickinson
JDRF and Becton Dickinson are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration announced. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes. |
|
| 07:56 EDT | | MDT | Medtronic InFuse sales unlikely to drop meaningfully, says Stifel
After examining Yale's review of Medtronic's InFuse program, Stifel doesn't see any significant surprises in the report that would trigger a meaningful downturn in sales of the product. The firm keeps a Hold rating on Medtronic. |
|
| 07:28 EDT | | AGN, MDT | Wells Faro to host a conference
 Subscribe for More Information |
|
| 07:22 EDT | | MDT | Impact to Medtronic from Infuse risk manageable, says Bernstein
After Yale reviewed Medtronic's Infuse product and found that it slightly increases cancer risk, Bernstein expects the impact on Medtronic's stock to be manageable, as Infuse makes up only 3% of the company's sales and less of its profits. The firm expects Infuse sales to drop by about 4% in FY14, but it keeps an Outperform rating on the stock. |
|
| 07:22 EDT | | BAYRY | Citigroup to host a conference
Subscribe for More Information |
|
| June 17, 2013 |
| 18:02 EDT | | MDT | Medtronic acknowledges findings from Yale review of Infuse bone graft
Subscribe for More Information |
|
| 09:19 EDT | | DVA | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:58 EDT | | BDX | Becton Dickinson price target raised to $115 from $95 at Argus
Argus increased its price target on Becton Dickinson as the firm expects the company to benefit from its new generic drug manufacturing business. The firm notes that this new business has high margins, and it keeps a Buy rating on the shares. |
| |
| 07:56 EDT | | BDX | Becton Dickinson management to meet with Deutsche Bank
Subscribe for More Information |
|
| 07:28 EDT | | BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| 07:07 EDT | | DVA | DaVita, Myriad RMB announces biomarker research collaboration
Subscribe for More Information |
|
| 07:02 EDT | | COV | Covidien announces publication of final results of Pipeline study
Covidien announced that the final results of the PUFs, Pipeline for Uncoilable or Failed Aneurysms, clinical study of its Pipeline embolization device have been published in the June issue of Radiology, the official peer-reviewed medical journal of the Radiological Society of North America. The Pipeline device met the trial’s primary endpoints for both effectiveness and safety. Based on these data, the Pipeline device was approved by the U.S. Food and Drug Administration on April 6, 2011. |
|
| 06:42 EDT |  | CI, HUM, WLP, AET | Choices provided by health insurance exchanges to vary widely, NY Times says
Subscribe for More Information |
|
| June 15, 2013 |
| 15:26 EDT | | AET | Aetna leaving individual insurance market in California, WSJ says
As the federal health law is set to reshape the insurance market in 2014, Aetna will stop selling health insurance to individual consumers in California at the end of 2013, says the Wall Street Journal. Reference Link |
|
| June 14, 2013 |
| 11:23 EDT |  | DVA | Options with increasing implied volatility: TWO SRPT LNCO LINE DVA
|
|
| 09:57 EDT | | MDT | Court ruling a minor negative for Edwards Lifesciences, says Leerink
Subscribe for More Information |
|
| 09:45 EDT | | MDT | Edwards lost first of three cases against Medtronic, says Wells Fargo
Subscribe for More Information |
|
| 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. |
| |
|
|
|
|
